scholarly journals Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice

PLoS ONE ◽  
2017 ◽  
Vol 12 (6) ◽  
pp. e0179099 ◽  
Author(s):  
Helene L. Kammoun ◽  
Tamara Louise Allen ◽  
Darren Colin Henstridge ◽  
Michael James Kraakman ◽  
Lone Peijs ◽  
...  
2005 ◽  
Vol 18 (2) ◽  
pp. 212-221 ◽  
Author(s):  
Haim Shapiro ◽  
Rafael Bruck

Non-alcoholic steatohepatitis (NASH) may be associated with a number of clinical conditions, but it occurs most commonly in patients with insulin resistance. There is as yet no established disease-modifying treatment, and a safe and broadly available agent that targets hepatic steatosis, insulin resistance, inflammation and fibrosis is necessary. The polyphenolic compound curcumin exhibits antioxidant and anti-inflammatory properties, inhibits NF-κB and activates PPAR-γ. In rodents, curcumin prevents dietary-induced hepatic steatosis, hepatic stellate cell activation and production of fibrotic proteins, and ameliorates steatohepatitis induced by the intake of alcohol or a methionine–choline-deficient diet. Indirect evidence suggests that curcumin may improve insulin sensitivity in diabetes and inflammatory states. The present paper reviews the numerous cellular and animal studies indicating that curcumin attenuates many of the pathophysiological processes involved in the development and progression of NASH. It is suggested that basic and clinical studies on curcumin in the development and progression of NASH are indicated.


2020 ◽  
Vol 178 ◽  
pp. 112958
Author(s):  
Eugenia Carril ◽  
María Pilar Valdecantos ◽  
Borja Lanzón ◽  
Santiago Angulo ◽  
Ángela M. Valverde ◽  
...  

2012 ◽  
Vol 123 (5) ◽  
pp. 323-332 ◽  
Author(s):  
Chiara Imarisio ◽  
Elisa Alchera ◽  
Salvatore Sutti ◽  
Guido Valente ◽  
Francesca Boccafoschi ◽  
...  

NEFA (non-esterified ‘free’ fatty acid)-mediated lipotoxicity plays a critical role in the pathogenesis of NASH (non-alcoholic steatohepatitis). In the light of the growing need for new therapeutic options for NASH, we investigated the action of A2aR (adenosine A2a receptor) stimulation against lipotoxicity. The effects of the A2aR agonist CGS21680 [2-p-(2-carboxyethyl)phenethylamino-5′-N-ethylcarboxyamidoadenosine] were evaluated ‘in vitro’ in liver cells exposed to SA (stearic acid) and ‘in vivo’ in rats with NASH induced by 8 weeks of feeding with an MCD diet (methionine/choline-deficient diet). In cultured hepatocytes, SA promoted apoptosis by inducing MKK4 (mitogen-activated protein kinase kinase 4)/SEK1 (stress-activated protein kinase/extracellular-signal-regulated kinase kinase-1) and JNK-1/2 (c-Jun N-terminal kinase-1/2) activation. CGS21680 addition prevented JNK-1/2 activation and reduced apoptosis without interfering with lipid accumulation. CGS21680 action required PI3K (phosphoinositide 3-kinase)/Akt-mediated block of MKK4/SEK1. Consistently, PI3K inhibition with wortmannin abolished the cytoprotective action of CGS21680 and reverted MKK4 inhibition. SA lipotoxicity was also prevented by transfecting HTC cells with a specific MKK4/SEK1 siRNA (small interfering RNA). In rats receiving the MCD diet, the development of NASH was associated with MKK4/SEK1 and JNK-1/2 activation. CGS21680 (0.5 mg/kg of body weight, intraperitoneal) administration to MCD-fed rats prevented JNK-1/2 activation by acting on MKK4/SEK1. CGS21680 also effectively reduced NASH-associated ALT (alanine aminotransferase) release, hepatocyte apoptosis, liver inflammation and fibrosis without affecting hepatic steatosis. Taken together, these results demonstrate that, by inhibiting JNK-1/2, A2aR stimulation reduces lipotoxicity and ameliorates NASH, giving a rationale to investigate A2aR agonists as possible new therapeutic agents in preventing fatty liver progression to NASH.


Inflammation ◽  
2007 ◽  
Vol 31 (2) ◽  
pp. 91-98 ◽  
Author(s):  
Suleyman Serdar Koca ◽  
Ibrahim Halil Bahcecioglu ◽  
Orhan Kursat Poyrazoglu ◽  
Ibrahim Hanifi Ozercan ◽  
Kazim Sahin ◽  
...  

2014 ◽  
Vol 4 (1) ◽  
Author(s):  
Takemi Rokugawa ◽  
Tomoya Uehara ◽  
Yusuke Higaki ◽  
Shuuichi Matsushima ◽  
Atsushi Obata ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document